Email this   Print this

Clinical Pharmacology of SSRI's References

References

1. Aberg-Wistedt A, Comparison between zimelidine and desipramine in endogenous depression: A cross-over study. Acta Psychiatr Scan. 1982;66:129-138
2. Aberg-Wistedt A, The antidepressant effects of 5-HT uptake inhibitors. Br J Psychiatry. 1989;155(suppl 8):32-40
3. Agundez JAG, Martinez C, Ladero JM, et al, Pharmacokinetics and drug disposition: Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther. 1994;55:10-14
4. Albers LJ, Reist C, Helmeste D, Vu R, Jang SW, Paroxetine shifts imipramine metabolism. Psychiatry Research. 1996; 59:189-196
5. Alderman J, Greenblatt D, Allison J, Preskorn S, Harrison W, Chung M, Desipramine pharmacokinetics with the selective serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline. Poster presented at the American Psychiatric Association Sesquicentennial Celebration, 1844-1994; May 21-26, 1994; Philadelphia, Pa
6. Altamura AC, Montgomery SA, Wernicke JF, The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry. 1988;153 (suppl 3):109-112
7. Altamura AC, Moro AR, Percudani M, Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994;26: 201-214
8. Andersen BB, Mikkelsen M, Vesterager A, et al, No influence of the antidepressant paroxetine on carbamazepine valproate and phenytoin. Epilepsy Res. 1991:201-204
9. Andersson T, Omeprazole drug interaction studies. Clin Pharmacokinet. 1991;21:195-212
10. Andersson T, Miners JO, Veronese ME, Birkett DJ, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol. 1994;38:131-137
11. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L, Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984;36:138-144
12. Baker GB, Coutts RT, Holt A, Metabolism and chirality in psychopharmaoclogy. Biol Psychiatry. 1994:36:211-213. Editorial
13. Balant LP, Pharmacokinetics in special populations. Presented at European Psychopharmacology Consensus Meeting as a satelilite meeting to the First International Congress on Hormones, Brain and Neuropscyhopharmacology; September 13-17, 1993; Rhodes, Greece
14. Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschlimann JM, Garrone G, Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol. 1986;31:449-455
15. Balant-Gorgia AE, Schulz P, Dayer P, et al, Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenki. 1982;232:215-222
16. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC, Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(suppl 350):102-106
17. Barbeau A, Roy M, Paris S, Cloutier T, Plasse L, Poirier J, Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet. 1985;2:1213-1216
18. Baumann P, Bertschy G, Pharmacodynamic and pharmacokinetic interactions of selective serotonin reuptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. Nord J Psychiatry. 1993;47(suppl 30):13-19
19. Baumann P, Jonzier-Perey M, Koeb L, Kupfer A, Tinguely D, Schopf J, Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Intl Clin Psychopharmacol. 1986;1:102-112
20. Baumann P, Rochat B, Comparative pharmacokinetics of selective serotonin reuptake inhibitors: A look behind the mirror. Intl Clin Psychopharmacol. 1995;10(suppl 1):15-21
21. Bayer AJ, Roberts NA, Allen EA, et al, The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scan. 1989;80(suppl 350):85-86
22. Benfield P, Ward A, Fluvoxamine: A review of its pharmacodyamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986; 32:313-334
23. Bergstrom RF, Lemberger L, Farid NA, Wolen RL, Clinical pharmacology and pharmacokinetics of fluoxetine: A review. Br J Psychiatry. 1988;153(suppl 3):47-50
24. Bergstrom RF, Peyton AL, Lemberger L, Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51:239-248
25. Bertilsson L, Aberg-Wistedt A, The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol. 1983;15:388-390
26. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T, Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348-355
27. Bertschy G, Vandel S, Allers G, Volmat R, Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol. 1991;40:119-120
28. Bertschy G, Vandel S, Francois T, et al, Metabolic interaction between tricyclic antidepressant and fluvoxamine and fluoxetine, a pharmacogenetic approach. Clin Neuropharm. 1992;15(suppl 1):78A-79A
29. Biglin KE, Faraon MS, Constance TD, Lieh-Lai M, Drug-induced torsades de pointes: A possible interaction of terfenadine and erythromycin. Ann Pharmacother. 1994; 28:282
30. Birgersson C, Morgan ET, Jornvall H, von Bahr C, Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P450 from human liver. Biochem Pharmacol. 1986;35:3165-3166
31. Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde O, Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol. 1985;28:553-557
32. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT, The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 1992;33:521-523
33. Boehnert MT, Lovejoy FH, Value of the QRS duration versus serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. 1985;313:474-479
34. Bolden-Watson C, Richelson E, Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52:1023-1029
35. Bonnet P, Vandel S, Nezelog S, Sechter D, Bizouard P, Carbamazepine, fluvoxamine: Is there a pharmacokinetic interaction? Therapie. 1992;47:165
36. Borys DJ, Setzer SC, Ling LJ, et al, Acute fluoxetine overdose: A report of 234 cases. Am J Emerg Med. 1992;10: 115-120
37. Bouquet S, Vandel S, Bertschy G, et al, Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results. Clin Neuropharmacol. 1992;15(suppl 1): 82A-83A
38. Breyer-Pfaff U, Pfandl B, Nill K, et al, Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isoenzymes. Clin Pharmacol Ther. 1992; 52:350-358
39. Brøsen K, Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions. Nord J Psychiatry. 1993;47(suppl 30):21-26
40. Brøsen K, Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics. Clin Pharmacokinet. 1990;18:220-239
41. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF, Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993;44:349-355
42. Brøsen K, Gram LF, Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol. 1989;37:155-160
43. Brøsen K, Gram LF, Kragh-Sorensen P, Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipiramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit. 1991;13:177-182
44. Brøsen K, Gram LF, Sindrup S, Skjelbo E, Nielson KK, Pharmacogenetics of tricyclic and novel antidepressants: recent developments. Clin Neuropharm. 1992;15(suppl 1): 80A-81A
45. Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L, Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol. 1986;30:679-684
46. Brøsen K, Otton SV, Gram LF, Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther. 1986;40:543-549
47. Brøsen K, Skjelbo E, Rasmussen BB, Puolsen HE, Loft S, Fluvoxamine is a potent inhibitor of cytochrome P4501A2 Biochem Pharmacol. 1993;45:1211-1214
48. Brøsen K, Zeugin T, Meyer UA, Role of P4502D6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther. 1991;49:609-617
49. Burke MJ, Silkey B, Preskorn SH, Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry. 1994;55 (suppl A): 42-52
50. Butler M, Lang N, Young J, et al, Determination of CYP 1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116-127
51. Cade JFJ, Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349-352
52. Callaham M, Kassel D, Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emer Med. 1985;14:1-9
53. Caporaso N, Hayes RB, Dosemeci M, et al, Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 1989;49:3675-3679
54. Caporaso N, Landi MT, Vineis P, Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics. 1991;1:4-19
55. Caporaso NE, Tucker MA, Hoover RN, et al, Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst. 1990;82:1264-1272
56. Caraco Y, Tateishi T, Wood AJJ, Ethnic effects on inhibition of drug metabolism. Clin Pharmacol Ther. 1994;55: 169. Abstract
57. Cardiac Arrhythmia Pilot Study (CAPS) Investigators, Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol. 1988;61: 501-509
58. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T, The role of S-mephenytoin 4’-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol. 1994;37:237-242
59. Clomipramine hydrochloride (Anafranil). Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics Data Production Company; 1995:596-599
60. Clozapine (Clozaril). Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics Data Production Company; 1995:2149-2153
61. Cooper RG, Evans DAP, Whibley EJ, Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet. 1984;21:27-33
62. Coulehan JL, Schulberg HC, Block MR, et al, Depressive symptomatology and medical co-morbidity in a primary care clinic. Intl J Psychiatry Med. 1990;20:335-347
63. Crane GE, Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatry Res Rep. 1957;8:142-152
64. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE, The effect of paroxetine and other specific serotonin reuptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol. 1991;32: 658P-659P
65. Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K, Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry. 1996;57(suppl 1):24-28
66. Cusack B, Nelson A, Richelson E, Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 1994;114:559-565
67. Dahl M, Nordin C, Bertilsson L, Enantioelective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit. 1991;13:189-194
68. Dalhoff K, Almdal TP, Bjerrum K, et al, Paroxetine in patients with cirrhosis. Psychopharmacol. 1991;103:B13
69. Danish University Antidepressant Group, Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986;90:131-138
70. Danish University Antidepressant Group, Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disorder. 1990;18:289-299
71. Darley J, Interaction between phenytoin and fluoxetine. Seizure. 1994;3:151-152
72. Davidson J, Seizures and bupropion: a review. J Clin Psychiatry. 1989;50:256-261
73. de Vries MH, Raghoebar M, Mathlener IS, van Harten J, Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit. 1992;14: 493-498
74. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K, Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry. 1996;57(suppl 1):20-23
75. Doogan DP, Caillard V, Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217-222
76. Dorian P, Sellers EM, Reed KL, et al, Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol. 1983;25:325-331
77. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF, Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25:71-79
78. Doyle GD, Laher M, Kelly JG, et al, The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand. 1989;80(suppl 350):89-90
79. Dufour H, Bouchacourt M, Thermoz P, et al, Citalopram -- a highly selective 5-HT reuptake inhibitor in the treatment of depressed patients. Intl Clin Psychopharmacol. 1987;2:225-237
80. Dunner DL, Dunbar GC, Optimal dose regimen for paroxetine. J Clin Psychiatry. 1992;53(suppl 2):21-26
81. Emrich HM, Berger M, Riemann D, von Zerssen D, Serotonin reuptake inhibition versus norepinephrine reuptake inhibition: a double-blind differential therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatrica. 1987;20:60-63
82. Eric LT, A prospective double-blind comparative multicentre study of paroxetine and placebo in preventing recurrent major depression episodes. Biol Psychiatry. 1991; 29(suppl 11):2545
83. Evans D, Antidepressant adverse effects and antidepressants in the medically ill. Am Soc Clin Psychopharm Progress Notes. 1995;6:22-25
84. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102-105
85. Fabre LF, Abuzzahab FS, Amin M, et al, Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995;38:592-602
86. Feighner JP, Cohn JB, Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985;46:20-25
87. Fleishaker JC, Hulst LK, A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994; 46:35-39
88. Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA, The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics. 1992; 2:128-134
89. Fluvoxamine maleate (Luvox). Compendium of Pharmaceuticals and Specialities. 30th ed. Ottawa, Ontario, Canada: Canadian Pharmaceutical Association; 1995:737-738
90. Folgia JP, Perel JM, Nathan RS, Pollock BG, Therapeutic drug monitoring (TDM) of fluvoxamine, a selective antidepressant. Clin Chem. 1990;36:1043. Abstract
91. Fonne-Pfister R, Bargetzi MJ, Meyer UA, MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450 buf-I, P450 dbl) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Comm. 1987;148: 1144-1150
92. Frank E, Kupfer DJ, Perel JM, et al, Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47:1093-1099
93. Fredricson OK, Kinetics of citalopram in man: plasma levels in patients. Prog NeuroPsychopharmacol Biol Psychiatry. 1982;6:311-318
94. Overo KF, Preliminary studies of the kinetics of citalopram in man. Eur J Clin Pharmacol. 1978;14:69-73
95. Fredericson OK, Toft B, Christophersen L, Gylding-Sabroe JP, Kinetics of citalopram in elderly patients. Psychopharmacol. 1985;86:253-257
96. Fritze J, Unsorg B, Lanczik M, Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991;84:583-584
97. Frommer DA, Kulig DA, Marx JA, Rumack B, Tricyclic antidepressant overdose: a review. JAMA. 1987;257:521-526
98. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW, Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropsychopharmacol. 1992; 31:997-1000
99. Gardner MJ, Ronfeld RA, Wilner KD, et al, Absence of a clinically meaningful effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Journal of Clinical Pharmacokinetics 32(suppl 1):43-49, 1997
100. Garnier R, Azoyan P, Chataigner D, Taboulet P, Dellattre D, Efthymiou ML, Acute fluvoxamine poisoning. J Intern Med Res. 1993;21:197-208
101. Gernaat HBPE, Van De Woude J, Touw DJ, Fluoxetine and parkinsonism in patients taking carbamazepine. Am J Psychiatry. 1991;148:1604-1605. Fluoxetine and parkinsonism in patients taking
102. Gidal BE, Anderson GD, Seaton TL, Miyoshi HR, Wilenksy AJ, Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit. 1993;15:405-409. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide
103. Glassman AH, Roose SP, Giardina EGV, Bigger JT Jr, Cardiovascular effects of tricyclic antidepressants. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987: 1437-1442
104. Goldstein JA, de Morais SM, Biochemistry and molecular biology of the human CYP 2C subfamily. Pharmacogenetics. 1994;4:285-299
105. Gonzalez FJ, Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 1992;13:346-352
106. Gonzalez FJ, Gelboin HV, Human cytochromes P450: evolution and cDNA-directed expression. Environmental Health Perspectives. 1992;98:81-85
107. Gonzalez FJ, Nebert DW, Evolution of the P450 gene superfamily: Animal-plant "warfare," molecular drive and human genetic differences in drug oxidation. Trends Genetics. 1990;6:182-186
108. Goodnick PJ, Pharmacokinetics of second generation of antidepressants: fluoxetine. Psychopharm Bull. 1991;27: 503-512
109. Gram L, Brøsen K, Kragh-Sorensen P, Christensen P, Steady-state plasma levels of E- and Z-10-OH-nortripty-line in nortriptyline-treated patients: significance of concurrent mediation and the sparteine oxidation phenotype. Ther Drug Monit. 1989;11:508-514. Gram L, Brøsen K, Kragh-Sorensen P, Christe
110. Gram LF, Hansen MGJ, Sindrup SH, et al, Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit. 1993;15:18-24
111. Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G, The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr Scand. 1989;80(suppl 350):95-98
112. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS, Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:479-486
113. Grimsley SR, Jann MW, Carter JG, D’Mello AP, D’Souza MJ, Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991; 50:10-15
114. Guengerich FP, Bioactivation and detoxication of toxic and carginogenic chemicals. Drug Metab Dispos. 1993; 21:1-6
115. Guengerich FP, Cytochrome P450 enzymes. Am Scientist. 1993;81:440-447
116. Guengerich FP, Human cytochrome P450 enzymes. Life Sci. 1992;50:1471-1478
117. Guengerich FP, Shimada T, Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol. 1991;4:391-407
118. Hartter S, Wetzel H, Hammes E, Hiemke C, Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacol. 1993; 110:302-308
119. Harvey AT, Preskorn SH, Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol. 1996;16:273-285
120. Harvey AT, Preskorn SH, Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry. 1995;52:783-784
121. Hayashi S, Watanabe J, Nakachi K, Kawajiri K, Genetic linkage of lung cancer-associated Mspl polymorphisms with amino acid replacement in hemo binding region of the human cytochrome P4501A1 gene. J Biochem. 1991;110:407-411
122. Hebenstreit, GF, Fellerer K, Zochling R, Zentz A, Dunbar GC, A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand. 1989;80(suppl 350)81-84
123. Hinmarch I, Subhan Z, Stoker MJ, The effects of zimelidine and amitriptyline on car driving and psychomotor performance. Acta Psychiatr Scand. 1983;68(suppl 308):141-146
124. Hiramatsu KT, Takahashi R, Mori A, et al, A multicentre, double-blind comparative trial of zimelidine and imipramine in primary major depressive disorders. Acta Psychiatr Scand. 1983;68(suppl 308):41-54
125. Holm M, Olesen F, Psykofarmakordination i almen praksis (Prescribing of psychotropic drugs in general practice). Ugskr Laeger. 1989;151:2122-2126
126. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr, Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8
127. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518
128. Hoyer D, Clark DE, Fozard JR, et al, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) Pharmacol Rev. 1994;46:157-203
129. Hyttel J, Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry. 1993;47 (suppl 30):5-12
130. Hyttel J, Bogeso KP, Perregaard J, Sanchez C, The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm. 1992;88:157-160. Hyttel J, Bogeso KP, Perregaard J, Sanchez C
131. Inaba T, Jurima M, Mahon WA, Kalow W, In vitro inhibition studies of two isozymes of human liver cytochrome P450: mephenytoin P-hydroxylase and sparteine monooxygenase. Drug Metab Dispos.1985;13:443-448
132. Ishizaki T, Chiba K, Manabe K, et al, Comparison of the effects of E3810 and omeprazole on diazepam pharmacokinetics in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1994;55:141. Abstract
133. Jacobsen FM, SSRI-induced sexual dysfunction. American Society of Clinical Psychopharmacology Progress Notes. 1994;5:1-4
134. Jalil P, Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry. 1992;55:412-413. Toxic reaction following the combined administration of fluoxetine and phenytoin
135. Janicak PG, Davis JM, Preskorn SH, Syd FJ Jr, Principles and Practices of Psychopharmacotherapy. Baltimore, Md: Williams and Wilkins; 1993
136. Jann MW, Carson SW, Grimsley SR, Erikson SM, Kumar A, Carter JG, Lack of effect of sertraline on the pharmacokinetics and pharmacodynamics of imipramine and its metabolites. Clin Pharm Therap. 1995;57:207. Abstract
137. Jerling M, Lindstrom L, Bondesson U, Bertilsson L, Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-374
138. Kaisary A, Smith P, Jaczq E, et al, Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 1987;47:5488-5493
139. Kalow W, Tyndale RF, Debrisoquine/sparteine monooxygenase and other P450s in brain. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergammon Press, Inc; 1992:649-656
140. Kasper S, Dotsch M, Vieira A, Kick H, Moller HJ, Plasma concentration of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharm. 1993;3:13-21
141. Kaye CM, Haddock RE, Langley PF, et al, A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;80(supp 350):60-75
142. Kelly MW, Perry PJ, Holstad SG, Garvey MJ, Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit. 1989;11:165-170
143. Kerr BM, Thummel KE, Wurden CJ, et al, Human liver carbamazepine metabolism. Role of CYP3A4 and CYP- 2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47:1969-1979
144. Ketter TA, Flockhart DA, Post RM, et al, The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15:387-398
145. Ketter TA, Post RM, Worthington K, Principles of clinically important drug interactions with carbamazepine. Part I and Part II. J Clin Psychopharmacol. 1991;11:198-203, 306-313
146. Kragh-Sorensen P, Overo KF, Peterson OL, Jensen K, Parnas W, The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol et Toxicol. 1981;48: 53-60
147. Krishna D, Klotz U, Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994;26:144-160
148. Kuhn R, The treatment of depressive states with G-22355 (imipramine hydrochloride). Am J Psychiatry. 1958;115: 459-464
149. Kunze K, Eddy AC, Gibaldi M, Trager W, Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality. 1991;3:24-29
150. Kupfer DJ, Longterm treatment of depression. J Clin Psychiatry. 1991;52(suppl 5):28-34
151. Kupfer DJ, Frank E, Perel JM, et al, Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769-773
152. Kupfer A, Preisig R, Pharmacogenetics of p-mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26:753-759
153. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimale BJ, Drug interation between sertraline and desipramine or imipramine. J Clin Pharmacol. 1994;34:1009-1033. Abstract
154. Laborit H, Huguenard P, Alluaume R, Un nouveau stabilisateur vegetatif, le 4560 RP. Presse Med. 1952; 60:206-208
155. Lader M, Melhuish A, Freka G, Fredericson, OK, Christensen V, The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol. 1986;31:183-190
156. Lane R, Baldwin D, Preskorn S, The SSRIs: advantages, disadvantages and differences. J Psychopharmacol. 1995; 9(suppl):163-178
157. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ, Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacol. 1991;104:323-327
158. Laursen AL, Mikkelsen PL, Rasmussen S, le Fevre Honore P, Paroxetine in the treatment of depression -- a randomized comparison with amitriptyline. Acta Psychiatr Scand. 1985;71:249-255
159. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR, Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985;46:14-19
160. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF, The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther. 1988;43:412-419
161. Lemoine A, Gautier JC, Azoulay D, et al, Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993;43:827-832
162. Lewis R, Trager W, Chan K, et al, Warfarin: stereo-chemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974;53:1607-1617
163. Lin L, Yang F, Ye Z, et al, Case-control study of cigarette smoking and primary hepatoma in an aflatoxin-endemic region of China: a protective effect. Pharmacogenetics. 1991;1:79-85
164. Lingjaerde O, Bratfos O, Bratlid T, Havg JO, A double-blind comparison of zimelidine and desipramine in endogenous depression. Acta Psychiatr Scand. 1983;68:22-30
165. Litovitz TL, Holm KC, Clancy C, Schmitz BF, Clark LR, Oderda GM, 1992 annual report of the American Association of Poison Control Centers Toxic Exposures Surveillance System. Am J Emerg Med. 1993;11:494-555
166. Lund J, Lomholt B, Fabricius J, Christensen JA, Bechgaard E, Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man. Acta Pharmacol et Toxicol. 1979; 44:289-295
167. Lundmark J, Scheel K, Thomsen I, Fjord-Larsen T, et al, Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand. 1989;80(suppl 350):76-80
168. Madsen H, Nielsen KK, Brøsen K, Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms -- a population study. Br J Clin Pharmacol. 1995;39:433-439
169. Marder SR, Meibach RC, Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835
170. Marsden CA, Tyrer P, Casey P, Seivewright N, Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. J Psychopharmacol. 1987;1:244-250
171. Mellstrom B, Bertilsson L, Sawe J, Schulz H, Sjoqvist F, E- and Z-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther. 1981;30:189-193
172. Miles MV, Tennison MB, Erythromycin effects on multiple-dose carbamazepine kinetics. Ther Drug Monit. 1989;11:47-52
173. Milne RJ, Goa KL, Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41:450-477
174. Montgomery SA, Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. Intl Clin Psychopharmacol. 1995;10(suppl 1):23-27
175. Montgomery SA, Dufour H, Brion S, et al, The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 1988;153(suppl 3):69-76
176. Montgomery SA, Evans R, Relapse prevention with antidepressants. Nord J Psychiatry. 1993;47(suppl 30):83-88
177. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P, The optimal dosing regimen for citalopram-a metaanalysis of nine placebo-controlled studies. Intl Clin Psychopharmacol. 1994;9(suppl 1):35-40
178. Montgomery SA, Rasmussen JG, Lyby K, Connor P, Tanghoj P, Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Intl Clin Psychopharmacol. 1992;6(suppl 5):65-70
179. Montgomery SA, Rasmussen JG, Tanghoj P, A 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Intl Clin Psychopharmacol. 1993;8:181-188
180. Murray M, Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metabolism Reviews. 1987;18:55-81
181. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K, Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 1991;51:5177-5180
182. Nathan RS, Perel JM, Pollock BG, Kupfer DJ, The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry. 1990; 51:367-372
183. Nebert DW, Proposed role of drug-metabolizing enzymes: regulation of steady-state levels of the ligands that effect growth, homeostatis, differentiation, and neuroendocrine functions. Mol Endocrinol. 1991;5:1203-1214
184. Nebert DW, Adesnik M, Coon MJ, et al, The P450 gene superfamily: recommended nomenclature. DNA. 1987;6:1-11
185. Nebert DW, Gonzalez FJ, P450 genes: structure, evolution and regulation. Ann Rev Biochem. 1987;56:945-993
186. Nebert DW, Nelson DR, Feyereisen R, Evolution of the cytochrome P450 genes. Xenobiotica. 1989;19:1149-1160
187. Nelson DR, Kamataki T, Waxman DJ, et al, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol. 1993;12:1-51
188. Nierenberg AA, Cole JO, Antidepressant adverse drug reactions. J Clin Psychiatry. 1991;52(suppl):40-47
189. Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK, Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Intl Clin Psychopharmacol. 1993;8:25-29
190. Nystrom C, Hallstrom T, Double-blind comparison between serotonin and adrenaline reuptake blocker in the treatment of depressed outpatients: clinical aspects. Acta Psychiatr Scand. 1985;72:6-15
191. Nystrom C, Hallstrom T, et al, Comparison between serotonin and adrenaline reuptake blocker in the treatment of depressed outpatients: a crossover study. Acta Psychiatr Scand. 1987;75:377-382
192. Ohmori S, Takeda S, Rikihisa T, Kiuchi M, Kanakubo Y, Kitada M, Studies on cytochrome P450 resonsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull. 1993;16:571-575
193. Orzechowska-Juzwenko K, Wiela A, Cieslinska A, Roszkowska E, Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. Cancer. 1987;59:1607-1610
194. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM, Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT uptake inhibitors. Clin Pharm Therap. 1994;55:141
195. Otton SV, Inaba T, Kalow W, Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci. 1983;32:795-800
196. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM, Inhibition by fluoxetine of cytochrome P-450 2D6 activity. Clin Pharm Therap. 1993;53:401-409
197. Overo KF, Preliminary studies of the kinetics of citalopram in man. Eur J Clin Pharmacol. 1978;14:69-73
198. Overmars H, Scherpenisse PM, Post LC, Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet. 1983;8:269-280
199. Palmer KJ, Benfield P, Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in nondepressive disorders. CNS Drugs. 1994; 1:57-87
200. Pato MT, Murphy DL, DeVane CL, Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol. 1991;11:224-225
201. Pearson HJ, Interaction of fluoxetine with carbamazepine. J Clin Psychiatry.1990;51:126
202. Perel JM, Shostak M, Gann E, Kantor SJ, Glassman AH, Pharmacodynamics of imipramine and clinical outcome in depressed patients. In: Gottschalk LA, Merlis S, eds. Pharmacokinetics of Psychoactive Drugs. New York, NY: Spectrum Publications; 1976:229-241
203. Perucca E, Gatti G, Cipolla G, et al, Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther. 1994;56:471-476
204. Perucca E, Gatti G, Spina E, Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1994;27:175-190
205. Pfandi B, Morike K, Winne D, Schareck W, Breyer-Pfaff U, Steroselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica. 1992;22:721-730
206. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK, The effect of enzyme induction on the cytochrome P450 mediated bioactivation of carbamazipine by mouse liver microsomes. Biochem Pharmacol. 1992;44:2307-2314
207. Pirmohamed M, Kitteringham NR, Guenther TM, Breckenridge AM, Park BK, An investigation of the formation of cytotoxic protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol. 1992; 43:1675-1682
208. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK, Metabolism and bioactivation of clozapine by human liver in vitro. J Pharm Exp Therap. 1995;272:984-990
209. Pollock B, Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry. 1994; 2:204-213
210. Preskorn SH, Antidepressant drug selection: criteria and options. J Clin Psychiatry. 1994;55(suppl A):6-22, 23-24, 98-100
211. Preskorn SH, Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. J Clin Psychiatry. 1995;56(suppl 6):12-21
212. Preskorn SH, Burke M, Harvey A, Carmichael C, Polypharmacy in psychiatry. Presented at the 129th NCDEU meeting; May 28-31, 1996; Boca Raton, Fla
213. Preskorn SH, Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):14-34
214. Preskorn SH, Should bupropion dosage be adjusted based upon therapeutic drug monitoring? Psychopharmacol Bull. 1991;27:637-643
215. Preskorn SH, Should rational drug development in psychiatry target more than one mechanism of action in a single molecule?. Intl Rev Psychiatry. 1995;7:17-28
216. Preskorn SH, Sudden death and tricyclic antidepressants (TCAs): A rare adverse event linked to high TCA plasma levels. Nord J Psychiatry. 1993;47(suppl 30):49-55
217. Preskorn SH, Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Intl Clin Psychopharmacol. 1994;9(suppl 3):13-19
218. Preskorn SH, What is the message in the alphabet soup of cytochrome P450 enzymes?. J Prac Psychiatry Behavioral Hlth. 1995;1:237-240
219. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S, Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98
220. Preskorn SH, Burke M, Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry. 1992;53(suppl 9):5-18
221. Preskorn SH, Fast GA, Therapeutic drug monitoring for antidepressants: Efficacy, safety and cost effectiveness. J Clin Psychiatry. 1991;52(suppl 6):23-33
222. Preskorn SH, Fast GA, Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry. 1992;53:160-162
223. Preskorn SH, Harvey A, Biochemical and clinical dose-response curves with sertaline. Clin Pharmacol Ther. 1996; 59:180
224. Preskorn SH, Harvey AT, Stanga C, Drug interactions: how to understand them and their role in patient care. In: Rush AJ, ed. Current Review of Mood Disorders. 1996. In press
225. Preskorn SH, Irwin HA, Toxicity of tricyclic antidepressants-kinetics, mechanism, intervention: a review. J Clin Psychiatry. 1982;43:151-156
226. Preskorn SH, Janicak PG, Davis JM, Ayd FJ, Advances in the pharmacotherapy of depressive disorders. In: Janicak PG, ed. Principles and Practices of Psychopharmacotherapy. Baltimore, Md: Williams and Wilkins; 1995:4
227. Preskorn SH, Jerkovich GS, Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors and the role of therapeutic drug monitoring. J Clin Psychopharmacol. 1990;10:88-95
228. Preskorn SH, Jerkovich GS, Beber JH, Widener P, Therapeutic drug monitoring of tricyclic antidepressants: a standard of care issue. Psychopharmacol Bull. 1989;25:281-284
229. Preskorn SH, Lane RM, Sertraline 50 mg daily: The optimal dose in the treatment of depression. Intl Clin Psychopharmacol. 1995;10:129-141
230. Preskorn SH, Mac DS, The implication of concentration/response studies of tricyclic antidepressants for psychiatric research and practice. Psychiatric Develop. 1984;2:201-222
231. Preskorn SH, Magnus RD, Inhibition of hepatic P450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull. 1994;30:251-259
232. Preskorn SH, Silkey B, Beber J, Dorey C, Antidepressant response and plasma concentrations of fluoxetine. Ann Clin Psychiatry. 1991;3:147-151
233. Prien RF, Kupfer DJ, Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986;143:18-23
234. Raghoebar M, Roseboom H, Kinetics of fluvoxamine in special populations. Poster presented at Symposium on Variability in Pharmacokinetics and Drug Response; October 3-5, 1988; Gothenburg, Germany
235. Rasmussen BB, Maenpaa J, Pelkonen O, et al, Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol. 1995;39:151-159
236. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III, Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363-369
237. Reimherr FW, Chouinard G, Cohn CK, et al, Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990;51(suppl B):18-27
238. Rettie AE, Korzekwa KR, Kunze KL, et al, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5:54-59
239. Richelson E, Pharmacology of antidepressants: Characteristics of the ideal drug. Mayo Clin Proc. 1994;69:1069-1081
240. Robert P, Montgomery SA, Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6-month study. Intl Clin Psychopharmacol. 1995;10(suppl 1):29-35
241. Robertson MM, Trimble MR, Depressive illness in patients with epilepsy: a review. Epilepsia. 1983;24(suppl 2):S109-S116
242. Rochat B, Amey M, Baumann P, Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Therap Drug Monit. 1995;17:273-279
243. Ronfeld RA, Tremaine LM, Wilner KD, Henry EB, Evaluation of the pharmacokinetic properties of sertraline and desmethylsertraline in elderly and young normal volunteers. Clin Pharmacokinet. In press
244. Roose SP, Glassman AH, Attia E, Woodring S, Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melanchia. Am J Psychiatry. 1994;151:1735-1739
245. Rowe H, Carmichael R, Lemberger L, The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci. 1978;23:807-812
246. Schenker S, Bergstrom RF, Wolen RL, Lemberger L, Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1988;44:353-359
247. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI, N-demethylation of amitriptyline in vitro: role of cytochrome P450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther. 1995;275: 592-597
248. Series HG, Drug treatment of depression in medically ill patients. J Psychosom Res. 1992;36:1-16
249. Shader RI, Greenblatt DJ, von Moltke LL, Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol. 1994;14:375-376. Editorial
250. Shank RP, Vaught JL, Pelley KA, Setler PE, McComsey DF, Maryanoff BE, McN-5652: a highly potent inhibitor of serotonin uptake. J Pharm Exp Therap. 1988;247:1032-1038
251. Shaw CA, Sullivan JT, Kadlec KE, Kaplan HL, Naranjo CA, Sellers EM, Ethanol interactions with serotonin uptake selective and nonselective antidepressants: fluoxetine and amitriptyline. Human Psychopharmacol. 1989;4:113-120
252. Sindrup SH, Brøsen K, Gram LF, Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: non-linearity and relation to the sparteine oxidation polymorphism. Clin Pharm Ther. 1992;51:288-295
253. Sindrup SH, Brøsen K, Gram LF, et al, The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51:278-287
254. Sindrup SH, Brøsen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF, Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993;15:11-17
255. Sjoerdsma T, Palfregman A, History of serotonin. In: Peroutka S, Whitaker-Azmitia P, eds. Neuropharmacology of Serotonin. New York, NY: Annals of the New York Academy of Science; 1990;600:2-9
256. Skjelbo E, Brøsen K, Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992; 34:256-261
257. Skjelbo E, Brøsen K, Hallas J, Gram LF, The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharm Therap. 1991; 49:18-23
258. Smith SJ, Cardiovascular toxicity of antihistamines. Otolaryngol Head Neck Surg. 1994;111:348-354
259. Sommi RW, Crismon ML. Bowden CL, Fluoxetine: a serotonin-specific second-generation antidepressant. Pharmacotherapy. 1987;7:1-15
260. Sperber AD, Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety. 1991;6:460-462
261. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F, Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit. 1993;15:247-250
262. Spina E, Birgersson C, von Bahr C, et al, Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharm Therap. 1984;36:677-682
263. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP, Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15:243-246
264. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM, Does sertraline inhibit CYP 2D6 after chronic dosing?. Clin Pharm Therap. 1995;57:151
265. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F, Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharm Therap. 1988;44:431-435
266. Sternbach H, The serotonin syndrome. Am J Psychiatry. 1991;148:705-713
267. Stevens JC, Wrighton SA, Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450 J Pharm Exp Therap. 1993;266:964-971
268. Swims MP, Potential terfenadine-fluoxetine interaction. Ann Pharmacotherapy. 1993;17:1404
269. Tasker TCG, Kaye CM, Zussman BD, Link CGG, Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand. 1989;80(suppl 350): 152-155
270. Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M, Interaction between fluvoxamine and theophylline. Pharmaceutical J. 1992;1:137
271. Tork I, Anatomy of the serotonergic system. In: Peroutka S, Whitaker-Azmitia P, eds. Neuropharmacology of Serotonin. New York, NY: Annals of the New York Academy of Science; 1990;600:9-35
272. Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ, Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatography. 1992;579:99-106
273. Tremaine LM, Wilner KD, Henry EB, Ronfeld RA, Absence of a biologically meaningful effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet. In press
274. van Harten J, Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24: 203-220
275. van Harten J, Stevens LA, Raghoebar M, Holland RL, Wesnes K, Cournot A, Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther. 1992;52:427-435
276. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharm Exp Therap. 1994;268:1278-1283
277. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo M, Harmatz J, Shader R, Inhibitors of alprazolam metabolism in vitro: effect of serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol. 1994; 38:23-31
278. von Moltke LL, Greenblatt DJ, Court MH, et al, Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharm. 1995;15:125-131
279. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI, In vitro prediction of the terfenadine-keto-conazole pharmacokinetic interaction. J Clin Pharmacol. 1994;34:1222-1227
280. Walker PW, Cole JO, Gardner EA, et al, Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54:459-465
281. Warrington SJ, Clinical implications of the pharmacology of sertraline. Intl Clin Psychopharmacol. 1991;6(suppl 2): 11-21
282. Watkins PB, Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin N Am. 1992;21: 511-526
283. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M, Low dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988;24:183-188
284. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL, Fixed dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164-168
285. Wilde MI, Plosker GL, Benfield P, Fluvoxamine: an updated review of its pharmacology and therapeutic use in depressive illness. Drugs. 1993;46:895-924
286. Wilkinson G, Guengerich FP, Branch RA, Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989;43:53-76
287. Wilner KD, Apseloff G, Gerber N, Henry EB, Lazar JD, Tremaine LM, Absence of a biologically meaningful effect of sertraline on the pharmacodynamics and protein binding of warfarin. Clin Pharmacokinet. In press
288. Wilner KD, Preskorn SH, The pharmacokinetics of sertraline. Clin Pharmacokinet. In press
289. Wolf ME, Bukowski ED, Conran J, et al, Polypharmacy: a problem of the decade of the nineties. American Psychiatric Association, 148th annual meeting; May 20-25, 1995; Miami, Fla. Abstract
290. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW, Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology. 1993;8:337-344
291. Wong DT, Fuller RW, Robertson DW, Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm Nord. 1990;2:171-180
292. Wood K, Swade C, Abou-Saleh M, Milln P, Coppen A, Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. Br J Clin Pharmacol. 1983;15(suppl 3):365S-368S
293. Woods DJ, Coulter DM, Pillans P, Interaction of phenytoin and fluoxetine. N Z Med J. 1994;107:19
294. Yasumori T, Nagata K, Yang SK, et al, Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics. 1993;3:291-301
295. Yun CH, Okerholm RA, Guengerich FP, Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metabolism and Disposition Diol Fate Chem. 1993;21:403-409
296. Zajecka J, Fawcett J, Schaff M, et al, The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991;52:66-68
297. Zimmermann M, Duruz H, Guinand O, et al, Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J. 1992;13:1002-1003
298. Zussman BD, Davie CC, Fowles SE, et al, Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol. 1995;39:550-551
299. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Narmatz JS, Shader RI, In vitro biotransformation of phenacetin to acetaminophen. Clin Pharm Therap. 1996;59:175
300. Centurrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG, Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol. 1994;14:119-125
301. Nemeroff CB, DeVane CL, Pollock BG, Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320
302. DeVane CL, Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med. 1994;97(suppl 6A): 13S-23S
303. Fleishaker JC, Hulst LK, A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994; 46:35-39
304. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS, Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:479-486
305. Olkkola KT, Aranko K, Luurila H, et al, A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53:298-305
306. Varhe A, Olkkola KT, Neuvonen PJ, Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther. 1994;56:601-607